Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KYMR NASDAQ:MESO NASDAQ:PCVX NYSE:QGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYMRKymera Therapeutics$78.89$83.18$28.06▼$103.00$6.49B2.06515,777 shs549,366 shsMESOMesoblast$15.20$15.01$9.88▼$21.50$1.97B2.09151,258 shs115,563 shsPCVXVaxcyte$47.30$56.43$29.08▼$65.00$6.83B1.31.69 million shs1.33 million shsQGENQiagen$35.23+0.2%$38.17$32.53▼$57.81$7.26B0.642.65 million shs1.20 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYMRKymera Therapeutics0.00%-4.04%-7.09%-10.79%+167.51%MESOMesoblast0.00%+1.40%-2.00%-8.87%+40.09%PCVXVaxcyte0.00%-9.72%-20.49%-21.51%+45.36%QGENQiagen0.00%+6.74%-8.22%-25.76%-20.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYMRKymera Therapeutics$78.89$83.18$28.06▼$103.00$6.49B2.06515,777 shs549,366 shsMESOMesoblast$15.20$15.01$9.88▼$21.50$1.97B2.09151,258 shs115,563 shsPCVXVaxcyte$47.30$56.43$29.08▼$65.00$6.83B1.31.69 million shs1.33 million shsQGENQiagen$35.23+0.2%$38.17$32.53▼$57.81$7.26B0.642.65 million shs1.20 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYMRKymera Therapeutics0.00%-4.04%-7.09%-10.79%+167.51%MESOMesoblast0.00%+1.40%-2.00%-8.87%+40.09%PCVXVaxcyte0.00%-9.72%-20.49%-21.51%+45.36%QGENQiagen0.00%+6.74%-8.22%-25.76%-20.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKYMRKymera Therapeutics 2.95Moderate Buy$118.1049.70% UpsideMESOMesoblast 2.33HoldN/AN/APCVXVaxcyte 2.63Moderate Buy$86.0081.82% UpsideQGENQiagen 2.50Moderate Buy$44.9827.67% UpsideCurrent Analyst Ratings BreakdownLatest MESO, PCVX, QGEN, and KYMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026QGENQiagen Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetHold$50.00 ➝ $36.005/18/2026QGENQiagen CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold5/12/2026QGENQiagen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/7/2026QGENQiagen TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$46.00 ➝ $40.005/6/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$106.004/30/2026KYMRKymera Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$119.004/30/2026QGENQiagen Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$43.004/29/2026QGENQiagen BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight$44.00 ➝ $38.004/29/2026QGENQiagen Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral ➝ Outperform$53.00 ➝ $43.004/29/2026QGENQiagen Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/29/2026QGENQiagen Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy$43.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKYMRKymera Therapeutics$39.21M165.51N/AN/A$18.72 per share4.21MESOMesoblast$17.20M114.41N/AN/A$4.67 per share3.25PCVXVaxcyteN/AN/AN/AN/A$20.75 per shareN/AQGENQiagen$2.09B3.47$3.41 per share10.33$16.17 per share2.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%8/10/2026 (Estimated)MESOMesoblast-$102.14M-$0.54N/AN/AN/AN/AN/AN/AN/APCVXVaxcyte-$766.63M-$6.88N/AN/AN/AN/A-32.51%-29.51%8/5/2026 (Estimated)QGENQiagen$424.88M$1.9118.4013.243.5019.16%14.40%8.40%8/4/2026 (Estimated)Latest MESO, PCVX, QGEN, and KYMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026QGENQiagen$0.54$0.54N/A$0.33$496.15 million$492.32 million5/6/2026Q1 2026PCVXVaxcyte-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/A4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million2/26/2026Q4 2025KYMRKymera Therapeutics-$0.77-$0.97-$0.20-$0.97$14.80 million$2.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKYMRKymera TherapeuticsN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/AQGENQiagen$0.260.74%N/A13.61%N/ALatest MESO, PCVX, QGEN, and KYMR DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/11/2026QGENQiagenannual$0.351.04%7/7/20267/7/20267/14/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKYMRKymera TherapeuticsN/A10.8110.81MESOMesoblast0.101.581.41PCVXVaxcyteN/A7.497.49QGENQiagen0.493.212.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKYMRKymera TherapeuticsN/AMESOMesoblast1.43%PCVXVaxcyte96.78%QGENQiagen70.00%Insider OwnershipCompanyInsider OwnershipKYMRKymera Therapeutics15.98%MESOMesoblast18.80%PCVXVaxcyte3.10%QGENQiagen9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionableMESOMesoblast80129.46 million105.12 millionOptionablePCVXVaxcyte160144.40 million139.92 millionOptionableQGENQiagen5,654206.07 million187.53 millionOptionableMESO, PCVX, QGEN, and KYMR HeadlinesRecent News About These CompaniesQiagen N.V. (NYSE:QGEN) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 24 at 2:19 AM | americanbankingnews.comQGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.May 21, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENMay 21, 2026 | prnewswire.comQIAGEN Stock Up on the Launch of AI-Powered Workflow Agent PlatformMay 21, 2026 | zacks.comQIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflowsMay 20, 2026 | businesswire.com3 Stocks in Focus That Recently Declared Dividend Hikes Amid High InflationMay 20, 2026 | zacks.comQiagen (QGEN) Securities Fraud Investigation - Levi & KorsinskyMay 20, 2026 | prnewswire.comQGEN INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Qiagen N.V.May 19, 2026 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENMay 19, 2026 | globenewswire.comQIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIAMay 19, 2026 | businesswire.comBarclays Remains a Hold on Qiagen (QGEN)May 18, 2026 | theglobeandmail.comQIAGEN INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Qiagen N.V.May 15, 2026 | globenewswire.comQGEN SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential ...May 15, 2026 | caledonianrecord.comCQiagen NV (QGEN) price target decreased by 13.91% to 46.28May 15, 2026 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V. - QGENMay 14, 2026 | prnewswire.comQGEN SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws ViolationsMay 14, 2026 | globenewswire.comLevi & Korsinsky Announces Investigation of Securities Claims Against Qiagen N.V. (QGEN)May 14, 2026 | globenewswire.comQIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 MillionMay 13, 2026 | businesswire.comQiagen N.V. (QGEN) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comQIAGEN to Appoint Dr. Metin Colpan as Honorary Chairman of the Supervisory Board, Continue Governance Renewal and Propose Increased Returns at 2026 Annual General MeetingMay 12, 2026 | businesswire.comM&T Bank Corp Takes $2.19 Million Position in Qiagen N.V. $QGENMay 9, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMESO, PCVX, QGEN, and KYMR Company DescriptionsKymera Therapeutics NASDAQ:KYMR$78.89 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$78.85 -0.04 (-0.05%) As of 05/22/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Mesoblast NASDAQ:MESO$15.20 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$15.17 -0.03 (-0.20%) As of 05/22/2026 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Vaxcyte NASDAQ:PCVX$47.30 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$48.09 +0.79 (+1.68%) As of 05/22/2026 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Qiagen NYSE:QGEN$35.23 +0.06 (+0.17%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$35.16 -0.06 (-0.18%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
